Stay updated on ONC-392 & Pembrolizumab in Platinum Resistant Ovarian Cancer Clinical Trial

Sign up to get notified when there's something new on the ONC-392 & Pembrolizumab in Platinum Resistant Ovarian Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ONC-392 & Pembrolizumab in Platinum Resistant Ovarian Cancer Clinical Trial page

  1. Check
    today
    Change Detected
    Summary
    The ClinicalTrials.gov site footer now displays revision v3.8.1 instead of v3.8.0. The study record content remains unchanged.
    Difference
    0.1%
    Check dated 2026-11-18T01:24:40.000Z thumbnail image
  2. Check
    7 days ago
    No Change Detected
  3. Check
    14 days ago
    Change Detected
    Summary
    The site footer revision number changed from v3.7.2 to v3.8.0.
    Difference
    0.1%
    Check dated 2026-11-03T21:56:13.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    A site-wide NIH notice says federal agencies are transitioning from “Artificial Intelligence” to “Super Intelligence,” and the displayed site revision advances from v3.7.1 to v3.7.2.
    Difference
    0.7%
    Check dated 2026-10-20T21:50:04.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision label changed from v3.7.0 to v3.7.1.
    Difference
    0.1%
    Check dated 2026-10-06T21:44:10.000Z thumbnail image
  6. Check
    56 days ago
    Change Detected
    Summary
    A new Study Status section was added to the record history on 2026-09-22, and a new version entry dated 2026-09-21 (version 14) was created to reflect updated status. Additionally, the prior entry dated 2026-04-13 was removed from the history.
    Difference
    0.4%
    Check dated 2026-09-22T23:10:33.000Z thumbnail image
  7. Check
    63 days ago
    Change Detected
    Summary
    The record history now includes a new revision labeled v3.7.0. The previous revision v3.6.6 has been removed, indicating a version update to the page rather than changes to the study content.
    Difference
    0.1%
    Check dated 2026-09-15T21:47:44.000Z thumbnail image

Stay in the know with updates to ONC-392 & Pembrolizumab in Platinum Resistant Ovarian Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ONC-392 & Pembrolizumab in Platinum Resistant Ovarian Cancer Clinical Trial page.